Collaboration to advance multiplexed biomarker panel for early Type 1 diabetes diagnosis

Genalyte (San Diego, CA) has launched a Type 1 diabetes multiplexed antigen panel that runs on the company's silicon photonics-driven Maverick detection system, and is the first multiplexed assay that measures seven autoantibodies associated with the destruction of pancreatic islet cells seen in Type 1 diabetes. The company is also collaborating with the Barbara Davis Center for Childhood Diabetes (BDC) at the University of Colorado School of Medicine (Aurora, CO) to further develop and test multiplexed antigen panels for the early detection of Type 1 diabetes.

Related: Multiplexed detection system from Genalyte garners CE mark approval
 
The T1D antigen panel was developed as part of the first phase of a Small Business Innovation Research (SBIR) grant awarded to the company to develop multiplexed assays for the early detection and monitoring of Type 1 diabetes.  The $500,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases also provides support for expansion of the approach to allow autoantibody response profiling by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.
 
George Eisenbarth, MD, PhD, and Liping Yu, MD, at BDC established assays for measuring islet autoantibodies, explains Martin Gleeson, PhD, chief scientific officer at Genalyte. Islet autoantobodies eventually destroy the pancreatic islet cells that produce insulin; to that end, the Maverick detection platform can detect and track the process from an early stage, when interventions to interrupt the disease process may be feasible, he says.
 
Available to diabetes researchers worldwide, the T1D antigen panel requires only a 2 to 5 μL serum or plasma sample and provides results in less than 15 minutes without the use of dyes, fluorescent probes, or radioactive labels. The panel measures autoantibodies to insulin, proinsulin, GAD 65, GAD 67, IA-2 (PTPRN, ICA512), phogrin (PTPRN2, IA-2ß), and ZnT8 (SLC30A8).

For more information, visit http://genalyte.com/maverick-type-1-diabetes-t1d-assay-kit/.         

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

POST A COMMENT

Related Articles

Live-cell imaging with parallelized RESOLFT nanoscopy

Super-resolution microscopy of large fields in living cells possible with sCMOS

Super-resolution microscopy using a novel fluorescence microscope has enabled a team of researchers to perform real-time nanoscopic imaging of large fields of living cells for the first time.

Fluorescence imaging method using SWIR light detects cancer early

Rutgers University researchers have developed a fluorescence imaging method that has potential to detect cancer and other diseases earlier than before, potentially reducing the need for biopsies.

Fluorescence approach can track HIV proteins' motion in real time

Researchers have developed technologies—one of which involves a fluorescence method—that allow investigators to track HIV proteins' movement on the virus surface, which may contribute to how it inf...

Light microscopy method speeds brain, spinal cord measurements

Researchers at the University of Miami (Florida), as a part of the Miami Project to Cure Paralysis, have turned to a light microscopy method to help answer questions that help define human spinal c...

BLOGS

BioOptics World editor-in-chief Barbara Goode

What is biophotonics?

At BioOptics World, our focus is photonics (including optics) for life sciences—that is, biophoto...

Nobel Prize honors super-resolution optical microscopy

"This year's prize is about how the optical microscope became a nanoscope," said Staffa...

High-res 3D optical: A tribute to Mats Gustafsson

Biologists will soon be able to see more in 3D, thanks to the Howard Hughes Medical Institute (HH...

Most Popular Articles


CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2014. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS